SEC Form 4 · accession 0001140361-18-016884
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Apr 2, 2018
Accepted (ET)
Apr 3, 2018 · 8:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 2, 2018 | M | 3,350 | $26.49 | A | 160,026 | D | |
| Common StockF1 | Apr 2, 2018 | S | 3,350 | $80.12 | D | 156,676 | D | |
| Common StockF1 | Apr 2, 2018 | M | 6,650 | $37.46 | A | 163,326 | D | |
| Common StockF1 | Apr 2, 2018 | S | 6,650 | $80.12 | D | 156,676 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F2 | $26.49 | Apr 2, 2018 | M | 3,350 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 3,350 | 1,875 | D |
| Stock Option (Right to buy Common Stock)F1,F2 | $37.46 | Apr 2, 2018 | M | 6,650 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 6,650 | 20,681 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
- F2Reflects the number of options outstanding after the transactions from this specific stock option grant.